DexCom (DXCM) Stock Forecast & Price Target

Q: What analysts cover DexCom?

DexCom has been rated by research analysts at Argus , Benchmark , BTIG Research , Canaccord Genuity Group , Citigroup , Deutsche Bank Aktiengesellschaft , JPMorgan Chase & Co. , Mizuho , Piper Sandler , Raymond James Financial , Robert W. Baird , Royal Bank Of Canada , Stifel Nicolaus , TD Cowen , Truist Financial , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$89.35 +1.42 (+1.61%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$89.88 +0.53 (+0.59%)

As of 09/18/2026 07:58 PM Eastern

Compare

DexCom - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
1

Hold
2

Buy
23

Based on 26 Wall Street analysts who have issued ratings for DexCom in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 1 has given a sell rating, 2 have given a hold rating, 21 have given a buy rating, and 2 have given a strong buy rating for DXCM.

Consensus Price Target

$89.08
-0.30% Downside

According to the 26 analysts' twelve-month price targets for DexCom, the average price target is $89.08. The highest price target for DXCM is $105.00, while the lowest price target for DXCM is $64.00. The average price target represents a forecasted downside of -0.30% from the current price of $89.35.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for DXCM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for DexCom and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DXCM Analyst Ratings Over Time

Type	Current Forecast 9/19/25 to 9/19/26	1 Month Ago 8/20/25 to 8/20/26	3 Months Ago 6/21/25 to 6/21/26	1 Year Ago 9/19/24 to 9/19/25
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	3 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	21 Buy rating(s)	21 Buy rating(s)	19 Buy rating(s)	14 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$89.08	$88.71	$84.83	$99.89
Forecasted Upside	-0.30% Downside	-1.68% Downside	17.06% Upside	48.10% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

DXCM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DXCM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

DexCom Stock vs. The Competition

Type	DexCom	Healthcare Companies	Broader Market
Consensus Rating Score	2.92	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	-0.30% Downside	754.93% Upside	18.43% Upside
News Sentiment Rating	Neutral News See Recent DXCM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/18/2026	Truist Financial 3 of 5 stars	Richard Newitter 1 of 5 stars	Set Target	Buy	$93.00 ➝ $102.00	+15.26%
9/18/2026	TD Cowen 3 of 5 stars	Joshua Jennings Not Rated	Reiterated Rating	Buy	$95.00	+7.35%
8/11/2026	Weiss Ratings 5 of 5 stars		Upgrade	Hold (C-) ➝ Hold (C)
8/4/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steve Silver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$86.00 ➝ $96.00	+11.08%
8/3/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Plovanic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$82.00 ➝ $90.00	+3.60%
7/31/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Strong-Buy	$94.00	+11.54%
7/31/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt O'Brien Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$88.00 ➝ $95.00	+27.45%
7/31/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$105.00	+24.59%
7/31/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$84.00 ➝ $88.00	+18.06%
7/31/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$80.00 ➝ $90.00	+20.74%
Get the Latest News and Ratings for DXCM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.
7/31/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$90.00 ➝ $95.00	+27.45%
7/31/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kendall Au Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$85.00 ➝ $90.00	+7.49%
7/31/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$90.00 ➝ $95.00	+14.08%
7/31/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$65.00 ➝ $82.00	-1.32%
7/31/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$85.00 ➝ $90.00	+10.34%
7/31/2026	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bruce D. Jackson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$77.00 ➝ $82.00	-0.33%
7/28/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$96.00	+26.92%
6/23/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kieran Ryan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$86.00	+24.51%
5/18/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Underweight	$67.00 ➝ $64.00	+3.85%
5/18/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Travis Steed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$100.00 ➝ $80.00	+24.53%
5/15/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
5/1/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$77.00	+25.35%
3/24/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	In-Line ➝ Outperform	$90.00	+36.49%
1/12/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight
12/16/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$92.00	+39.97%
10/1/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kate McShane Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$104.00 ➝ $89.00	+37.98%
9/8/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Lichtman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/21/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	T. Perez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
2/3/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Issie Kirby Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$85.00 ➝ $115.00	+32.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:39 PM ET.

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 18, 2026. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com.

DexCom
Bull Case

Here are some ways that investors could benefit from investing in DexCom, Inc.:

DexCom, Inc. recently reported strong financial performance for the quarter ended July 30, 2026, beating consensus estimates with earnings per share of $0.70 compared to the expected $0.61, while also exceeding revenue projections with $1.31 billion in sales, indicating robust demand for its continuous glucose monitoring systems.
The stock is currently trading at $89.35, which is near its 52-week high of $92.59, reflecting a significant upward trend from its 52-week low of $54.11 and suggesting strong investor confidence in the company's growth trajectory and market position.
Analyst sentiment remains positive, with TD Cowen reaffirming a "buy" rating and setting a price target of $95.00, which implies potential upside from the current price, while the overall consensus rating stands at "Moderate Buy" with a target price of $88.71, indicating institutional support for the stock.
DexCom, Inc. maintains a healthy balance sheet with a debt-to-equity ratio of 0.47 and a current ratio of 1.73, demonstrating financial stability and the ability to meet short-term obligations, which reduces financial risk for investors.
The company continues to innovate in the diabetes care space with its latest products, including the Dexcom G7 and Dexcom G6 CGM systems, which are designed to provide real-time glucose monitoring and support more informed treatment decisions, positioning the company as a leader in medical technology.

DexCom
Bear Case

Investors should be bearish about investing in DexCom, Inc. for these reasons:

Insider selling has been notable recently, with multiple executives and directors, including Nicholas Augustinos and Michael Brown, selling shares in September 2026, which may signal a lack of confidence in the stock's near-term performance or a desire to lock in gains.
The stock's price-to-earnings ratio of 35.32 is relatively high compared to the broader market, suggesting that the stock may be overvalued if earnings growth does not continue to outpace expectations, posing a risk of a potential correction.
Short interest has increased slightly, with 17,626,435 shares shorted as of August 31, 2026, representing a 4.68% short percentage of the float, indicating that some investors are betting against the stock's future performance.
DexCom, Inc. does not pay a dividend, with a dividend yield of 0.00%, which may be a drawback for income-focused investors who prefer stocks that provide regular cash distributions.
The company faces competition in the continuous glucose monitoring market, and any failure to maintain its technological edge or market share could impact its revenue growth and profitability, especially as new entrants or existing competitors introduce new products.

DXCM Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for DexCom is $89.08, with a high forecast of $105.00 and a low forecast of $64.00.

26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There is currently 1 sell rating, 2 hold ratings, 21 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DXCM shares.

According to analysts, DexCom's stock has a predicted downside of -0.30% based on their 12-month stock forecasts.

Over the previous 90 days, DexCom's stock had 2 upgrades and 1 downgrade by analysts.

DexCom has been rated by research analysts at Argus, Benchmark, BTIG Research, Canaccord Genuity Group, Citigroup, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Mizuho, Piper Sandler, Raymond James Financial, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like DexCom more than other "healthcare" companies. The consensus rating for DexCom is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how DXCM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With DexCom Recommendations

MarketBeat monitors more than a dozen sources for DexCom analyst ratings, with the most recent rating issued on 9/18/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Stock Forecast & Price Target